Lassa Virus Nanobodies Bind GPC Trimer to Neutralize Infection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine development efforts for Lassa fever have been hindered by the highly glycosylated Lassa virus glycoprotein complex (LASV GPC) inducing a weak and inconsistent immune response, and the scarcity of neutralizing antibodies, which are critical for effective vaccine design.
Innovation Solution
Development of single-domain camel VHH and shark VNAR monoclonal antibodies that specifically bind to the LASV GPC with high affinity, capable of neutralizing pseudotyped virus expressing LASV GPC, and their use in various formats such as fusion proteins, CARs, and immunoconjugates for diagnostic and therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine development approaches using LASV GPC are used, then vaccine candidates can be developed, but the immune response induced is weak and inconsistent due to high glycosylation
Solution Approach 1:
The patent extracts and isolates specific neutralizing antibody regions (nanobodies) that recognize conserved epitopes on the GPC trimer, separating the effective neutralizing component from the problematic highly glycosylated full GPC structure. This extraction of key neutralizing regions allows development of vaccines that induce consistent immune responses without the interference of variable glycosylation patterns.
Solution Approach 2:
The patent changes the molecular parameters of the vaccine candidate by using engineered nanobodies with optimized binding properties instead of the native highly glycosylated GPC. These nanobodies have modified structural parameters that enable consistent recognition of conserved GPC epitopes, producing reliable immune responses across different formulations and hosts.
2Reliability
If extensive screening of convalescent patient antibodies is performed to find neutralizing antibodies, then neutralizing antibodies can be identified, but the process is time-consuming and resource-intensive with only 16 antibodies found after analyzing over 100 antibodies
Solution Approach 1:
The patent performs preliminary identification of conserved neutralizing epitopes on the GPC trimer structure before conducting extensive antibody screening. By pre-characterizing the key neutralizing regions and using these as targets for library screening, the patent dramatically reduces the time and resources needed to identify neutralizing antibodies, finding functional nanobodies much more efficiently than traditional convalescent serum screening.
3Reliability
If GPC trimer structure is used as vaccine candidate, then it represents the major viral antigen, but the highly glycosylated nature induces weak immune response
Solution Approach 1:
The patent introduces engineered nanobodies as intermediary molecules that bridge the gap between the highly glycosylated GPC trimer and the immune system. These nanobodies serve as mediators that recognize conserved epitopes on the GPC trimer through their constant regions, translating the structural information of the glycosylated antigen into consistent B-cell activation and antibody production, overcoming the masking effect of glycosylation.
Data Source
AI summary
Single-domain monoclonal antibodies that specifically bind Lassa virus glycoprotein (GPC) are described. The single-domain antibodies (“nanobodies”) were isolated from camel (VHH) and shark variable new antigen (VNAR) phage display libraries panned against a stabilized form of the GPC trimer. The GPC-specific nanobodies, and conjugates thereof, can be used for the diagnosis and treatment of a Lassa virus infection.